Anti-CNGB1/GARP monoclonal antibody
The Alternative Names of target: CNGB1, GARP,Cyclic nucleotide-gated channel beta-1,CNG channel beta-1,Cyclic nucleotide-gated cation channel 4 (CNG channel 4, CNG-4, CNG4), Cyclic nucleotide-gated cation channel gamma, Cyclic nucleotide-gated cation channel modulatory subunit, Glutamic acid-rich protein (GARP),CNG4,GAR1,GARP,RP45,CNCG2,CNCG4,GARP2,RCNC2,RCNCb,CNCG3L,CNGB1B,RCNCbeta
Pre-made anti-CNGB1/GARP monoclonal antibody (mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research.
Go
to CNGB1/GARP products collection
>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-IO045-Ab-1/ GM-Tg-hg-IO045-Ab-2 | Anti-Human CNGB1/GARP monoclonal antibody | Human |
GM-Tg-rg-IO045-Ab-1/ GM-Tg-rg-IO045-Ab-2 | Anti-Rat CNGB1/GARP monoclonal antibody | Rat |
GM-Tg-mg-IO045-Ab-1/ GM-Tg-mg-IO045-Ab-2 | Anti-Mouse CNGB1/GARP monoclonal antibody | Mouse |
GM-Tg-cynog-IO045-Ab-1/ GM-Tg-cynog-IO045-Ab-2 | Anti-Cynomolgus/Rhesus macaque CNGB1/GARP monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-IO045-Ab-1/ GM-Tg-felg-IO045-Ab-2 | Anti-Feline CNGB1/GARP monoclonal antibody | Feline |
GM-Tg-cang-IO045-Ab-1/ GM-Tg-cang-IO045-Ab-2 | Anti-Canine CNGB1/GARP monoclonal antibody | Canine |
GM-Tg-bovg-IO045-Ab-1/ GM-Tg-bovg-IO045-Ab-2 | Anti-Bovine CNGB1/GARP monoclonal antibody | Bovine |
GM-Tg-equg-IO045-Ab-1/ GM-Tg-equg-IO045-Ab-2 | Anti-Equine CNGB1/GARP monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. |
GM-Tg-hg-IO045-Ab-1/ GM-Tg-hg-IO045-Ab-2;
GM-Tg-rg-IO045-Ab-1/ GM-Tg-rg-IO045-Ab-2;
GM-Tg-mg-IO045-Ab-1/ GM-Tg-mg-IO045-Ab-2; GM-Tg-cynog-IO045-Ab-1/ GM-Tg-cynog-IO045-Ab-2; GM-Tg-felg-IO045-Ab-1/ GM-Tg-felg-IO045-Ab-2; GM-Tg-cang-IO045-Ab-1/ GM-Tg-cang-IO045-Ab-2; GM-Tg-bovg-IO045-Ab-1/ GM-Tg-bovg-IO045-Ab-2; GM-Tg-equg-IO045-Ab-1/ GM-Tg-equg-IO045-Ab-2 |
Products Name | Anti-CNGB1/GARP monoclonal antibody |
Format | mab |
Target Name | CNGB1/GARP |
Protein Sub-location | Transmembrane Protein |
Category of antibody | Therapeutics Target, Immuno-oncology Target |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) |
IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-CNGB1/GARP monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution |
Lyophilized from GM's Protein Stability Buffer2
(PSB2,Confidential Ingredients) or PBS
(pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data/case study
Click to get more Data/Case study about the product.
About Gmab
GMab, developed by GeneMedi, constitutes an
advanced library of recombinant
monoclonal antibodies, each meticulously
designed to target specific molecular
entities. Leveraging the sophisticated
capabilities of GM’s Taurus™ and LIBRA™
platforms, GMab synthesizes antibodies
characterized by high binding affinity,
exceptional physicochemical stability, and
optimal developability profiles.
Through
expression in mammalian cell lines, GMab has
been established as a paradigmatic
reference antibody. It holds significance in
myriad domains of biological drug
discovery, encompassing cellular cultivation,
innovative assay methodologies,
strategic animal model systematization, in-depth
pharmacokinetic & pharmacodynamic
(PK/PD) modeling, and intricate mechanism of
action (MOA) investigations.
Comments
No comments yet.